Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adial Pharmaceuticals ( (ADIL) ) has shared an update.
On May 23, 2025, Adial Pharmaceuticals received a notice from Nasdaq for not meeting the minimum stockholders’ equity requirement of $2.5 million, with their equity reported at $2,126,662 as of March 31, 2025. To address this, the company conducted a best efforts offering on June 18, 2025, raising approximately $3.6 million, which they believe has brought them back into compliance with Nasdaq’s requirements. However, Nasdaq will continue to monitor their compliance, and failure to maintain it may result in delisting.
The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Adial Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for addiction and related disorders. The company is committed to addressing unmet medical needs in this market segment.
Average Trading Volume: 8,163,324
Technical Sentiment Signal: Sell
Current Market Cap: $5.02M
Find detailed analytics on ADIL stock on TipRanks’ Stock Analysis page.